Metastatic Tumors

Updated: April 26, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

vemurafenib

960

Tablet

Orally 

every 12 hrs

Continue the therapy until disease progression or unacceptable toxicity occurs

cisplatin

Renal dose adjustment
In case of renal impairment, the dose is decreased by 25% if CrCl is between 10 and 50 mL/min. If CrCl is above 10 mL/min, then administer a dose that is 50 % of the initial dose:

The recommended dose of cisplatin via IV administration is 20 mg/m2/day for five days initially and then repeated every three weeks in combination with bleomycin and etoposide

zanidatamab

It is a novel bispecific antibody studied for the treatment of locally advanced or metastatic HER2-expressing cancers under phase 1 of clinical trail
Administer a dose up to 30 mg/kg intravenously every 2 or 3 weeks

vemurafenib

Safety and efficacy are not studied  

vemurafenib

Refer adult dosing

Future Trends